FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...
Symptom-based liver enzyme and triglyceride testing is proposed for isotretinoin patients without risk factors to reduce low-value care, transient abnormality anxiety, and out-of-pocket costs. Delphi ...
Identify the differences between a PBM and a PBA solution when it comes to a pharmacy benefit offering. Examine how testing benefit changes within a production environment help prevent claim ...
Improving outcomes in chronic conditions will require eliminating friction and creating a connected foundation that supports people continuously. For the millions of Americans living with a chronic ...
Centanafadine XR 280 mg QD significantly reduced AISRS total scores at week 8 versus placebo (LS mean change -18.5 vs -12.6; treatment difference -5.87). Improvement in comorbid anxiety was ...
TriNetX EHR analysis of 16,569 vitiligo patients versus matched controls demonstrated higher rates of depression, anxiety, panic disorder, insomnia, and nonorganic sexual dysfunction, with slightly ...
Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...
Broad formulary uptake includes unrestricted access via UnitedHealthcare, Express Scripts, Cigna, Optum Rx, and TRICARE, with prior authorization common among some Blue Cross plans and CVS Caremark.
Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...
Cohorts included 1,653 AL, 1,055 ATTRwt-CM, and 59 dual-diagnosis patients; only 53%–66% had any relevant test documented, and just 40%–49% had AL-specific workups. Complete monoclonal protein testing ...
An in-depth look at multiple myeloma treatment with a focus on bispecific antibodies. A special Managed Healthcare Executive supplement on the current treatment of multiple myeloma with an emphasis on ...
This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results